Vasopressin (Arginine Vasopressin/ADH): Complete Research Profile — V1/V2 Receptor Biology, Water Balance, and Vasoconstriction Research (2026)

# Vasopressin (Arginine Vasopressin / AVP): The Antidiuretic Neuropeptide Governing Water Balance, Stress, and Social Behavior Research

Introduction

Arginine vasopressin (AVP) — also known as antidiuretic hormone (ADH) — is a cyclic nonapeptide synthesized in the hypothalamus that has become one of the most extensively studied signaling molecules in neuroendocrinology (PMID: 42716550). Despite being only nine amino acids in length, AVP exerts far-reaching effects across multiple organ systems: regulating water reabsorption in the kidney, modulating cardiovascular tone, orchestrating the stress axis, and influencing complex social and emotional behaviors in the central nervous system.

For dosing, reconstitution, and protocol details, see our Desmopressin (DDAVP) Dosage Protocol Guide — Reconstitution, Intranasal vs Subcutaneous, Research Use (2026).

As a research compound, vasopressin occupies a unique position at the intersection of renal physiology, cardiovascular biology, neuroendocrinology, and behavioral neuroscience. The neuropeptide's three distinct receptor subtypes — V1a, V1b, and V2 — each couple to different intracellular signaling cascades and mediate physiologically distinct responses, giving researchers a rich pharmacological toolkit to dissect specific aspects of AVP biology.

This profile covers the molecular structure of AVP, its receptor pharmacology, the major research areas currently under investigation, its relationship to the structurally homologous oxytocin, and the analogs most commonly used in preclinical research.

> **Research Use Only (

References

• •PMID: 42708282
• •PMID: 42706772
• •PMID: 41363127

RUO) Notice:** Arginine vasopressin and its analogs are research chemicals intended exclusively for laboratory and in vitro investigation. This content is purely educational. These compounds are not approved for human or veterinary use outside of regulated clinical contexts and should not be used for self-experimentation.

---

Molecular Structure and Biosynthesis

Vasopressin is a cyclic nonapeptide with the sequence Cys-Tyr-Phe-Gln-Asn-Cys-Pro-Arg-Gly-NH₂. The six N-terminal residues form a ring stabilized by an intramolecular disulfide bond between the two cysteine residues (positions 1 and 6), while a flexible three-residue tail (Pro-Arg-Gly-NH₂) extends from the ring. The arginine residue at position 8 is the defining feature of the arginine form — in most mammals this is the predominant isoform, while pigs and hippopotamuses express lysine vasopressin (LVP) with lysine at position 8.

AVP is synthesized as a precursor protein (prepro-AVP) in magnocellular neurons of the paraventricular nucleus (PVN) and supraoptic nucleus (SON) of the hypothalamus. After signal peptide cleavage, the pro-AVP precursor is packaged into neurosecretory vesicles and transported along axonal projections to nerve terminals in the posterior pituitary, where enzymatic cleavage separates AVP from neurophysin II and copeptin. All three fragments are co-secreted into the bloodstream in equimolar amounts — a property that has made copeptin a stable, easy-to-measure surrogate biomarker for AVP secretion in clinical research settings.

Structurally, AVP differs from oxytocin by only two amino acids: position 3 (phenylalanine vs. isoleucine) and position 8 (arginine vs. leucine). This extraordinary structural similarity is evolutionarily ancient — comparative genomic studies suggest the oxytocin/vasopressin signaling system dates back at least 600 million years, predating the vertebrate lineage, with both peptides thought to have diverged from a common ancestral nonapeptide, vasotocin (Freeman et al., 2020).

---

Vasopressin Receptor Subtypes

AVP exerts its effects through three G-protein-coupled receptor (GPCR) subtypes, each encoded by separate genes and coupled to distinct signaling pathways (Koshimizu et al., 2012):

V1a Receptor (AVPR1A)

The V1a receptor is the most widely distributed vasopressin receptor in the body, expressed in vascular smooth muscle, the liver, myometrium, platelets, adipocytes, and extensively throughout the central nervous system — including the septum, hippocampus, amygdala, cortex, and hypothalamus. V1a couples to Gq/11, activating phospholipase C (PLC) and downstream protein kinase C (PKC) signaling, leading to increased intracellular calcium.

Peripheral V1a activation mediates vasoconstriction, platelet aggregation, and hepatic glycogenolysis. Centrally, V1a is the primary receptor implicated in social behavior, anxiety, aggression, and pair bonding — making it a target of intense neuroscience research.

V1b Receptor (AVPR1B)

The V1b receptor (also called V3R) is expressed primarily in the anterior pituitary corticotrophs and in discrete hippocampal and limbic neurons. Like V1a, it couples to Gq/11 and activates PLC/PKC signaling. Its defining physiological role is the potentiation of corticotropin-releasing hormone (CRH)-induced adrenocorticotropin (ACTH) release from the pituitary — a critical node in HPA axis regulation.

V1b knockout studies in mice demonstrated markedly reduced HPA axis activity under both resting and stress conditions, establishing V1b as an essential component of the stress response (Lolait et al., 2007).

V2 Receptor (AVPR2)

The V2 receptor is expressed almost exclusively on principal cells of the renal collecting duct. Unlike V1 receptors, V2 couples to Gs, activating adenylyl cyclase and increasing intracellular cAMP. The cardinal effect of V2 activation is the insertion of aquaporin-2 (AQP2) water channels into the apical membrane of collecting duct cells, dramatically increasing water permeability and enabling concentration of urine. This antidiuretic effect is the classical action of AVP and the basis for the alternative name "antidiuretic hormone."

Loss-of-function mutations in AVPR2 cause X-linked nephrogenic diabetes insipidus, while mutations in the AVP gene itself cause central (arginine vasopressin deficiency, AVP-D) diabetes insipidus. Conversely, inappropriately elevated AVP activity causes the syndrome of inappropriate antidiuresis (SIAD), the most common cause of hyponatremia in hospitalized patients.

---

Water Balance and Osmoregulation Research

AVP's role in water homeostasis is the most thoroughly characterized aspect of its biology. Release from the posterior pituitary is triggered by:

• •Osmoreceptors in the hypothalamic circumventricular organs that sense plasma osmolality increases as small as 1–2%
• •Baroreceptors and volume receptors in the heart and carotid sinus, activated by hypovolemia or hypotension (a ~10–15% volume reduction threshold)
• •Non-osmotic stimuli including nausea, hypoglycemia, hypoxia, and certain pharmacological agents

Once released, AVP binds renal V2 receptors, initiating a cascade that phosphorylates AQP2 and drives its trafficking to the collecting duct apical membrane. Water then flows down its osmotic gradient from tubular lumen into the hypertonic medullary interstitium.

Research into the molecular mechanisms of AQP2 trafficking has expanded considerably. Cryo-electron microscopy work on the V2 receptor-Gs signaling complex has revealed the structural basis for high-affinity AVP binding and receptor activation (Yin et al., 2021), opening avenues for structure-based drug design of V2 modulators.

Tolvaptan and Vaptans Research

The vaptans — non-peptide V2 receptor antagonists — represent the most clinically translated pharmacological tools for AVP research. Tolvaptan (Samsca/Jynarque) selectively blocks V2, producing aquaresis (electrolyte-free water excretion) without significant natriuresis. Research using tolvaptan has:

• •Established V2's essential role in water retention in heart failure and cirrhosis
• •Explored therapeutic potential in autosomal dominant polycystic kidney disease (ADPKD)
• •Investigated specific V2 receptor mutations that cause nephrogenic DI and their pharmacological rescue

---

Cardiovascular Research

Circulating AVP exerts significant cardiovascular effects primarily through V1a receptors on vascular smooth muscle and V2-mediated renal water retention. In preclinical models, AVP:

• •Acts as a potent vasoconstrictor (V1a-mediated), increasing systemic vascular resistance
• •Stimulates V1a-mediated myocardial hypertrophy at high concentrations
• •Is elevated in conditions of circulatory stress including heart failure, hemorrhage, and septic shock

Plasma AVP/copeptin levels are markedly elevated in patients with chronic heart failure, reflecting a homeostatic compensatory attempt to maintain perfusion pressure. However, chronic V1a and V2 activation contributes to the maladaptive ventricular remodeling and fluid retention characteristic of decompensated heart failure.

Research into non-selective vasopressin receptor antagonism (conivaptan, which blocks both V1a and V2) has advanced understanding of the relative contributions of each receptor subtype to the cardiovascular pathophysiology of heart failure. The finding that V1a antagonism may theoretically improve cardiac output while V2 antagonism drives the aquaretic effect has guided pharmacological strategies in this area.

---

HPA Axis and Stress Response Research

One of the most active areas of AVP research concerns its role as a co-secretagogue in the hypothalamic-pituitary-adrenal (HPA) axis. Under acute stress, CRH is released from parvocellular PVN neurons into the portal circulation, stimulating pituitary ACTH secretion. AVP, co-released from the same neurons, acts synergistically with CRH to amplify ACTH release via V1b receptors on corticotrophs.

The relative dominance of AVP over CRH in driving ACTH release shifts under different conditions:

• •Acute stress: CRH is the predominant driver; AVP plays an amplifying role
• •Chronic stress: AVP becomes increasingly dominant as CRH receptors undergo desensitization, while V1b receptor expression and sensitivity is maintained
• •HPA hyperactivity (as in major depressive disorder): Overactivation of the AVP-V1b axis is a proposed mechanism for the documented HPA dysregulation in depression

V1b receptor knockout mouse models have proven invaluable for dissecting these contributions. V1b⁻/⁻ mice show attenuated ACTH and corticosterone responses to forced swim and restraint stress, without affecting baseline HPA tone under non-stressful conditions (Tanoue et al., 2004).

V1b Antagonism in Depression and Anxiety Research

The hyperactivity of the AVP-V1b system in mood disorders has motivated substantial research into selective V1b antagonists as potential antidepressant/anxiolytic tools. Compounds such as SSR149415 (nelivaptan) and related molecules have been characterized extensively in preclinical models (Griebel & Holsboer, 2012):

• •Dose-dependent reduction in anxiety-related behavior in elevated plus maze, open field, and social defeat paradigms
• •Attenuation of CRH-induced corticosterone release
• •Antidepressant-like effects in chronic mild stress models

A 2023 comprehensive review summarized the growing evidence implicating V1b receptor hyperactivity as a potentially druggable target in major depression, PTSD, and related disorders characterized by HPA axis overdrive (Dumais & Bhatt, 2023).

---

Social Behavior and Neuroscience Research

Perhaps the most scientifically exciting frontier of vasopressin research involves the peptide's central effects on social behavior, cognition, and affiliation. The V1a receptor's dense expression in the limbic system — particularly the lateral septum, central amygdala, and bed nucleus of the stria terminalis — positions it to modulate:

Pair Bonding and Affiliation

Comparative studies across vole species demonstrated that monogamous prairie voles exhibit a distinctly different pattern of V1a receptor expression in the reward circuitry compared to non-monogamous meadow voles. This finding inspired decades of research exploring vasopressin as a neurochemical substrate of affiliative behavior and pair bonding — a complementary role to the well-characterized pro-social effects of oxytocin (Grinevich et al., 2015).

Aggression Research

V1a receptors in the lateral septum and hypothalamus regulate offensive aggression in rodent models. Selective V1a antagonists produced dose-dependent reductions in aggression without affecting locomotor activity or anxiety, suggesting a specific role in regulating the motivational/affective aspects of aggressive behavior. Research on the AVPR1A gene polymorphisms in humans has found associations with trait aggression and impulsivity, though mechanistic interpretation remains complex.

Autism Spectrum Disorder Research

The link between AVP signaling and social behavior has generated significant research interest in AVP's potential role in autism spectrum disorder (ASD). Multiple lines of evidence include:

• •AVPR1A gene associations with ASD susceptibility (Yirmiya et al., 2006)
• •Lower cerebrospinal fluid AVP levels observed in some ASD cohorts
• •Intranasal AVP administration improving social behavior scores in children with ASD in small-scale trials

The selective V1a antagonist balovaptan was evaluated in a 12-week Phase 2 clinical trial (VANILLA) in men with ASD. While the primary outcome (SRS-2 social responsiveness scale) was not met, secondary measures of adaptive behavior showed improvement, motivating continued investigation with refined patient stratification (Umbricht et al., 2017).

---

Memory and Cognitive Function Research

Early studies demonstrated that centrally administered AVP facilitated memory consolidation and retrieval in rodent models, while V1a or V2 antagonists impaired these processes. Subsequent research has attempted to disentangle vasopressinergic contributions to different memory phases:

• •Acquisition and encoding: Intra-hippocampal AVP injection enhanced spatial learning in water maze paradigms
• •Consolidation: Post-training systemic or intracerebroventricular AVP improved retention in avoidance learning
• •Retrieval: AVP facilitated retrieval of previously learned discriminations in appetitive tasks

The mechanisms involve modulation of hippocampal theta oscillations and long-term potentiation — effects mediated predominantly by V1a receptors in hippocampal CA1 and CA3 subfields (Koshimizu et al., 2012). Whether these findings translate meaningfully to primate cognition remains an active area of inquiry.

---

Mood Disorders Research

Beyond the HPA axis angle, AVP has been investigated as a potential biomarker and mechanistic driver of mood pathology. A comprehensive 2024 review in Psychiatry and Clinical Neurosciences examined AVP's role across affective disorders:

• •Plasma and CSF AVP levels are elevated in major depressive disorder (MDD), particularly in melancholic subtypes
• •AVP hypersecretion from hypothalamic parvocellular neurons correlates with HPA hyperactivity markers
• •V1b receptor variants have been associated with altered stress-related emotional reactivity
• •Chronic stress-induced AVP/CRH ratio shifts in the PVN may represent a biomarker of treatment-resistant depression phenotypes

The convergence of HPA dysregulation, elevated central AVP, and mood pathology in these studies suggests that the vasopressinergic system could yield both diagnostic biomarkers and novel therapeutic targets for treatment-resistant depression (Hu et al., 2024).

---

Vasopressin vs. Oxytocin: Distinct Research Tools

Because AVP and oxytocin differ by only two amino acids, understanding their distinct roles requires careful pharmacological dissection. At pharmacological concentrations, each peptide can cross-activate the other's receptors — a source of considerable experimental confound in early research.

Key differences for research purposes:

The structural divergence in positions 3 and 8 is sufficient to drive strong receptor selectivity when binding to native receptors — V1a/V1b/V2 all prefer the aromatic residue at position 3 (phenylalanine in AVP), while the oxytocin receptor prefers the aliphatic residue (isoleucine). This principle has guided the design of selective peptide analogs for research.

---

Research Analogs and Tools

Several synthetic analogs of vasopressin have been developed as research tools to probe specific receptor subtypes:

Desmopressin (DDAVP / 1-deamino-8-D-arginine-vasopressin)

Desmopressin is a modified AVP analog featuring deamination of the N-terminal cysteine and D-arginine substitution at position 8. These modifications confer:

• •~3000-fold selectivity for V2 over V1a (eliminating pressor activity)
• •Extended plasma half-life due to reduced proteolytic susceptibility
• •Oral/intranasal bioavailability

Desmopressin is the gold-standard V2-selective agonist tool compound in kidney physiology research and is also used to model nocturnal enuresis and central diabetes insipidus in preclinical settings.

Terlipressin

Terlipressin is a prodrug of lysine-vasopressin with preferential V1a activity. It is used experimentally as a vasoconstrictor tool in hepatorenal syndrome models and in GI hemorrhage research, providing sustained V1a-mediated vasoconstriction.

[Phe²,Orn⁸]-OT (Ornipressin) and V1a-Selective Agonists

Several research-grade cyclic peptides have been designed for high V1a selectivity for use in cardiovascular and behavioral pharmacology studies.

Peptide-based V1a Antagonists

Research-grade V1a antagonists including d(CH₂)₅[Tyr(Me)²]AVP and Manning compound have been used extensively in preclinical behavioral pharmacology to block central V1a signaling and investigate social behavior, memory, and aggression.

---

Diabetes Insipidus Research: AVP Deficiency and Resistance

Vasopressin research has important translational dimensions in the study of diabetes insipidus (DI). The current nomenclature revision (endorsed by a joint Endocrine Society/ERA working group in 2022) now designates:

• •AVP-D (AVP Deficiency): formerly "central DI" — inadequate AVP production due to hypothalamic/pituitary damage or genetic mutations in the AVP gene
• •AVP-R (AVP Resistance): formerly "nephrogenic DI" — intact AVP secretion but impaired V2 receptor signaling, typically due to AVPR2 mutations (X-linked) or AQP2 mutations

Research into AVP-R has been particularly productive. Studies have characterized over 200 AVPR2 mutations causing nephrogenic DI, with functional classification revealing mutations that cause misfolding and ER retention (Class 2) as potential targets for pharmacological chaperone rescue. Tolvaptan and related V2 ligands can act as pharmacological chaperones for specific mutations, rescuing receptor surface expression and partial function — a research approach with broad implications for GPCR channelopathy research (Bockenhauer et al., 2020).

---

Research Considerations and Stability

For laboratory use, arginine vasopressin presents specific handling considerations:

Stability: The disulfide bond in the ring structure renders AVP susceptible to reduction under strongly reducing conditions (e.g., DTT-containing buffers). The peptide is generally stable at −80°C in lyophilized form for years. In solution, peptide-grade water or 0.1% acetic acid is preferred over PBS or phosphate buffers, which can promote dimerization via disulfide exchange at higher pH.

Oxidation: Exposed to air or oxidizing conditions, the free disulfide can form inter-molecular disulfide bonds. Aliquoting stock solutions under inert atmosphere and working at pH 4–5 reduces this risk.

Biological activity assays: Standard V2 receptor activity is measured via cAMP accumulation in HEK293 cells expressing human AVPR2. V1a and V1b activity is measured via IP1 accumulation (downstream of PLC) or intracellular Ca²⁺ flux using fluorescent indicators.

---

Clinical Forms: Pitressin and Vasostrict

Vasopressin exists in two FDA-approved injectable formulations used in clinical and research settings:

Pitressin (Vasopressin Injection, USP)

Pitressin is synthetic arginine vasopressin for injection at a concentration of 20 units/mL. It carries FDA approval for two indications: prevention and treatment of postoperative abdominal distention, and treatment of abdominal radiographic procedures to dispel interfering gas. In the research context, Pitressin is the canonical tool compound for studying endogenous vasopressin's V1a (vasoconstrictor) and V2 (antidiuretic) effects in vivo, given its identical pharmacological profile to endogenous AVP.

Vasostrict (Vasopressin Injection 20 units/mL)

Vasostrict received FDA approval in 2014 specifically for vasodilatory shock — a landmark indication that established vasopressin as a first-line vasopressor in distributive shock states. Its mechanism in shock differs from catecholamine vasopressors: while norepinephrine acts through adrenergic receptors (which are downregulated in prolonged septic shock), vasopressin acts through V1a receptors whose expression and responsiveness is maintained even in late catecholamine-refractory shock.

The Vasopressin and Septic Shock Trial (VASST) established that low-dose vasopressin (0.03 units/min IV) could replace a component of norepinephrine requirements in septic shock without increasing adverse events, and demonstrated improved outcomes in less severe shock subgroups (Russell et al., 2008). The VANCS trial subsequently demonstrated vasopressin's superiority over norepinephrine in vasoplegic syndrome following cardiac surgery ([Hajjar et al., 2017]()).

---

Vasopressor Research: Septic Shock and Vasodilatory States

Vasopressin's role as a vasopressor in distributive shock has become one of its most clinically significant research areas. In septic shock, endogenous AVP levels paradoxically fall during the later phases — a phenomenon termed "relative vasopressin deficiency" — despite the severe hypotension that would normally trigger maximal AVP release (Sharshar et al., 2003). This deficiency likely reflects depletion of posterior pituitary AVP stores and autonomic dysfunction.

Key research findings in vasopressor research include:

• •Catecholamine-sparing effect: Low-dose exogenous vasopressin (0.01–0.04 units/min) can reduce norepinephrine requirements by 30–50% in septic shock, while maintaining mean arterial pressure
• •V1a receptor maintenance: Unlike adrenergic receptors, V1a receptors are not significantly downregulated during prolonged sepsis, making vasopressin effective when catecholamines have diminishing returns
• •Renal protective effects: Some research suggests vasopressin may reduce acute kidney injury rates in septic shock — potentially through redistribution of renal cortical blood flow — though this remains an area of active investigation ([Gordon et al., 2010]())
• •Vasoplegic syndrome: Post-cardiac bypass vasoplegic syndrome — characterized by profound vasodilation and low vascular resistance despite preserved cardiac output — is now a primary research model for vasopressin's V1a-mediated vasopressor mechanism

The combination of vasopressin with corticosteroids (hydrocortisone) in septic shock — explored in the VANISH trial ([Gordon et al., 2016]()) — reflects the interplay between the vasopressinergic and HPA axes in critical illness, linking the cardiovascular and endocrine research applications of this peptide.

---

Dosing in Research Literature

The following dosing parameters appear in published preclinical and clinical research literature. These figures are provided as reference for understanding published studies only and are not dosing recommendations.

In Vivo Rodent Models

• •Vasopressor studies (rat): Intravenous infusion of 0.1–10 mU/kg/min to study dose-dependent pressor effects; bolus doses of 10–100 ng/kg IV for acute blood pressure challenge protocols
• •Antidiuretic studies: Subcutaneous doses of 0.5–5 mU/kg to examine dose-dependent reductions in urine output and increases in urine osmolality
• •Social behavior / CNS: Intracerebroventricular (ICV) microinfusion of 0.1–1 µg in 1–5 µL vehicle into lateral ventricle or target structures (septum, amygdala) to study V1a-mediated behavioral effects; intranasal administration at 1–5 µg in behavioral pharmacology studies
• •HPA axis activation: ICV or intraperitoneal doses of 1–10 µg used to stimulate ACTH/corticosterone in V1b-mediated stress models

In Vitro

• •V2 receptor assays: AVP concentrations of 1 nM–1 µM in HEK293 or collecting duct cell lines; EC50 at V2 approximately 0.3–1 nM
• •V1a assays: EC50 approximately 1–5 nM in vascular smooth muscle cells or recombinant AVPR1A systems
• •V1b assays: EC50 approximately 1–3 nM in anterior pituitary cells or recombinant AVPR1B systems

Clinical Research Reference (Vasostrict / Pitressin)

• •Septic shock vasopressor: 0.03–0.04 units/min continuous IV infusion (fixed dose, not titrated to effect)
• •Vasoplegic syndrome: 0.03–0.1 units/min IV; maximum typically 0.1 units/min in research protocols
• •DI (central) replacement: Aqueous vasopressin 5–10 units IM/SC q6–8h (largely superseded by desmopressin in practice)

---

Summary

Arginine vasopressin is a nine-amino-acid neuropeptide that controls water balance via V2 receptors in the kidney, regulates cardiovascular tone and stress responses via V1a and V1b receptors, and modulates complex social, emotional, and cognitive behaviors through central V1a receptor circuits.

As a research tool, AVP and its receptor-selective analogs have enabled the dissection of renal osmoregulation, HPA axis physiology, the neurochemistry of social behavior, and the molecular pathology of diabetes insipidus. Emerging research continues to probe the vasopressinergic system's roles in mood disorders, autism spectrum disorder, and metabolic regulation.

Its structural kinship with oxytocin — differing by just two amino acids — makes the AVP/OT nonapeptide axis a compelling comparative model for understanding how subtle molecular changes in ancestral neuropeptide scaffolds can produce profoundly different biological functions across evolution.

---

References

1. Koshimizu TA et al. Vasopressin V1a and V1b receptors: from molecules to physiological systems. Physiol Rev. 2012;92(4):1813-1864. PubMed

2. Lolait SJ et al. The vasopressin V1b receptor critically regulates hypothalamic-pituitary-adrenal axis activity under both stress and resting conditions. J Clin Invest. 2007;117(1):166-174. PMC

3. Tanoue A et al. The HPA axis response to stress in V1b receptor knockout mice. J Neuroendocrinol. 2004. PMC

4. Grinevich V & Ludwig M. Central and peripheral actions of oxytocin and vasopressin: linking pituitary neuropeptides and their receptors to social neurocircuits. Neuroscience. 2015. PMC

5. Freeman SM et al. Comparison of the distribution of oxytocin and vasopressin 1a receptors in rodents reveals conserved and derived patterns of nonapeptide evolution. J Neuroendocrinol. 2020. PubMed

6. Dumais KM & Bhatt DL. Targeting the AVP V1b receptor system in depression. Front Psychiatry. 2023. PMC

7. Hu Y et al. Arginine vasopressin in mood disorders: a potential biomarker of disease pathology and target for pharmacologic intervention. Psychiatry Clin Neurosci. 2024. PMC

8. Umbricht D et al. A single dose, randomized, controlled proof-of-mechanism study of a novel vasopressin 1a receptor antagonist (RG7713) in high-functioning adults with autism spectrum disorder. Neuropsychopharmacology. 2017. DOI

9. Kim SJ et al. Association between the AVPR1a gene and autism in a family-based study. Mol Psychiatry. 2002. PubMed

10. Bockenhauer D et al. Tolvaptan pharmacological chaperone rescue of V2R mutations in nephrogenic diabetes insipidus. Sci Rep. 2020. Nature

---

Further Reading:

• •Oxytocin: The Nonapeptide Redefining Neuroendocrine and Social Behavior Research
• •Orexin A and Orexin B (Hypocretins): The Hypothalamic Neuropeptides Governing Arousal, Metabolism, and Oncology Research
• •PACAP (Pituitary Adenylate Cyclase-Activating Polypeptide): The Pleiotropic Neuropeptide Driving Neuroscience and Stress Research
• •Galanin: The Pleiotropic Neuropeptide Bridging Neuroscience, Metabolic, Pain, and Oncology Research
• •Dosage Chart
• •Half-Life Calculator

8. Russell JA et al. Vasopressin versus norepinephrine infusion in patients with septic shock (VASST). N Engl J Med. 2008;358(9):877-887. PubMed

10. Sharshar T et al. Depletion of neurohypophyseal content of vasopressin in septic shock. Crit Care Med. 2003;31(3):497-500. PubMed